Casdatifan + Zimberelimab for Kidney Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this study is to see whether the drug casdatifan is safe and effective either by itself or in combination with the drug zimberelimab in participants with resectable clear cell renal cell carcinoma (ccRCC).
The names of the study drugs involved in this study are:
* Casdatifan (a type of HIF-2α inhibitor)
* Zimberelimab (a type of monoclonal antibody)
Who Is on the Research Team?
Wenxin Xu, MD
Principal Investigator
Dana-Farber Cancer Institute
Are You a Good Fit for This Trial?
This trial is for adults over 18 with certain stages of kidney cancer (ccRCC) who are planning to have surgery. They should be relatively healthy, able to perform daily activities, and have normal blood counts and liver function tests. A confirmed diagnosis of ccRCC by biopsy is required, along with a measurable tumor.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Casdatifan daily for 21-day cycles, with Zimberelimab administered on Day 1 for Group B
Surgery
Participants undergo standard of care nephrectomy
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Casdatifan
- Zimberelimab
Trial Overview
The study is testing the safety and effectiveness of Casdatifan alone or combined with Zimberelimab in patients before they undergo kidney cancer surgery. Casdatifan inhibits HIF-2α, which may help stop cancer growth; Zimberelimab targets immune checkpoints to fight off cancer cells.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
* 16 participants will be enrolled and will complete the following: * Baseline visit * Cycle 1 through 3 (21 day cycles): * Days 1 - 21: Predetermined dose of Casdatifan 1x daily * Day 1: Predetermined dose of Zimberelimab * Standard of care nephrectomy * Follow up for up to 3 years
16 participants will be enrolled and will complete the following: * Baseline visit * Cycle 1 through 3 (21 day cycles): --Days 1 - 21: Predetermined dose of Casdatifan 1x daily * standard of care nephrectomy * Follow up for up to 3 years
Find a Clinic Near You
Who Is Running the Clinical Trial?
Dana-Farber Cancer Institute
Lead Sponsor
Arcus Biosciences, Inc.
Industry Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.